FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W50606585> ?p ?o ?g. }

• W50606585 endingPage "184" @default.
• W50606585 startingPage "165" @default.
• W50606585 abstract "The weight of the published evidence suggest that there is clinically significant immune recovery in a sizable fraction of HIV-infected patients who achieve suppression of viral replication. At the same time, it is clear that very few patients regain normal (i.e. equivalent to pre-infection) immune function, at least after the follow-up periods available so far. The experience from bone-marrow transplantation or intensive chemotherapy in adults suggests that such kind of immune reconstitution is unlikely (at least with treatments limited to stopping virus replication) once the immune system has been sufficiently damaged. It is also clear that effective immunity to HIV is not achieved in a significant proportion of patients. These findings have implications for both basic research and clinical practice. From the laboratory perspective, besides the urgent need to characterize the protective immunity to HIV (if it exists), it would be desirable to find some simple measure of the immune function of patients who receive therapy. The combination of markers of immune activation together with CD4 cell count and viral load should be further evaluated in this context. Regarding clinical practice, it is likely that prophylaxes for opportunistic infections can be discontinued uneventfully in the majority of patients responding to HAART. Although the evidence is not yet conclusive, all available data suggest this will be the case. Given that there is significant immune reconstitution even in advanced disease, it is tempting to consider if this fact can be used to support antiviral therapy recommendations that are less aggressive than the current ones. HIV eradication by pharmacologic means alone does not seem possible yet, and no effective immune response to HIV seems to be generated by starting therapy in the asymptomatic (as opposed to acute infection) stage of the disease. At the same time, the follow-up studies on prolonged antiretroviral therapy suggest that virologic failure will take place despite many months of seemingly adequate suppression. This fact, taken together with the side effects and inconvience of current antiretroviral regimens, can be used to support an argument in favor of evaluating strategies to treat later rather than earlier." @default.
• W50606585 created "2016-06-24" @default.
• W50606585 creator A5042319833 @default.
• W50606585 creator A5081451978 @default.
• W50606585 date "2002-02-22" @default.
• W50606585 modified "2023-09-27" @default.
• W50606585 title "Immune Reconstitution in HIV Infection" @default.
• W50606585 cites W1982448824 @default.
• W50606585 doi "https://doi.org/10.3109/9780203908778-8" @default.
• W50606585 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10885760" @default.
• W50606585 hasPublicationYear "2002" @default.
• W50606585 type Work @default.
• W50606585 sameAs 50606585 @default.
• W50606585 citedByCount "42" @default.
• W50606585 countsByYear W506065852012 @default.
• W50606585 countsByYear W506065852013 @default.
• W50606585 countsByYear W506065852014 @default.
• W50606585 countsByYear W506065852015 @default.
• W50606585 countsByYear W506065852016 @default.
• W50606585 countsByYear W506065852017 @default.
• W50606585 countsByYear W506065852019 @default.
• W50606585 countsByYear W506065852021 @default.
• W50606585 crossrefType "book-chapter" @default.
• W50606585 hasAuthorship W50606585A5042319833 @default.
• W50606585 hasAuthorship W50606585A5081451978 @default.
• W50606585 hasConcept C126322002 @default.
• W50606585 hasConcept C142462285 @default.
• W50606585 hasConcept C151730666 @default.
• W50606585 hasConcept C177713679 @default.
• W50606585 hasConcept C203014093 @default.
• W50606585 hasConcept C2779196057 @default.
• W50606585 hasConcept C2779341262 @default.
• W50606585 hasConcept C2779343474 @default.
• W50606585 hasConcept C2780648854 @default.
• W50606585 hasConcept C2780727368 @default.
• W50606585 hasConcept C2911091166 @default.
• W50606585 hasConcept C3013748606 @default.
• W50606585 hasConcept C71924100 @default.
• W50606585 hasConcept C86803240 @default.
• W50606585 hasConcept C8891405 @default.
• W50606585 hasConceptScore W50606585C126322002 @default.
• W50606585 hasConceptScore W50606585C142462285 @default.
• W50606585 hasConceptScore W50606585C151730666 @default.
• W50606585 hasConceptScore W50606585C177713679 @default.
• W50606585 hasConceptScore W50606585C203014093 @default.
• W50606585 hasConceptScore W50606585C2779196057 @default.
• W50606585 hasConceptScore W50606585C2779341262 @default.
• W50606585 hasConceptScore W50606585C2779343474 @default.
• W50606585 hasConceptScore W50606585C2780648854 @default.
• W50606585 hasConceptScore W50606585C2780727368 @default.
• W50606585 hasConceptScore W50606585C2911091166 @default.
• W50606585 hasConceptScore W50606585C3013748606 @default.
• W50606585 hasConceptScore W50606585C71924100 @default.
• W50606585 hasConceptScore W50606585C86803240 @default.
• W50606585 hasConceptScore W50606585C8891405 @default.
• W50606585 hasLocation W506065851 @default.
• W50606585 hasLocation W506065852 @default.
• W50606585 hasOpenAccess W50606585 @default.
• W50606585 hasPrimaryLocation W506065851 @default.
• W50606585 hasRelatedWork W1553825651 @default.
• W50606585 hasRelatedWork W1978162700 @default.
• W50606585 hasRelatedWork W2030531895 @default.
• W50606585 hasRelatedWork W2035492084 @default.
• W50606585 hasRelatedWork W2402149178 @default.
• W50606585 hasRelatedWork W2951205651 @default.
• W50606585 hasRelatedWork W3201659230 @default.
• W50606585 hasRelatedWork W4221035744 @default.
• W50606585 hasRelatedWork W4283515582 @default.
• W50606585 hasRelatedWork W4285045497 @default.
• W50606585 isParatext "false" @default.
• W50606585 isRetracted "false" @default.
• W50606585 magId "50606585" @default.
• W50606585 workType "book-chapter" @default.